Subscribe To
Regencell bioscience's covid-19 candidate shows encouraging action on mild to moderate symptoms
Regencell Bioscience Holdings Limited (NASDAQ: RGC) announced the results from the EARTH efficacy trial of its COVID-19 ...
February 17, 2022, 11:40 am
Open orphan client sees positive results in human challenge study
Open Orphan PLC (AIM:ORPH, OTC:OPORF) has highlighted positive results of a human challenge study assessing Enanta Pharmaceuticals (NASDAQ:ENTA)' resp...
February 17, 2022, 8:31 am
Open orphan client sees positive results in human challenge study
Open Orphan PLC (AIM:ORPH, OTC:OPORF) has highlighted positive results of a human challenge study assessing Enanta Pharmaceuticals (NASDAQ:ENTA)' resp...
February 17, 2022, 8:31 am
Open orphan client sees positive results in human challenge study
Open Orphan PLC (AIM:ORPH, OTC:OPORF) has highlighted positive results of a human challenge study assessing Enanta Pharmaceuticals (NASDAQ:ENTA)' resp...
February 17, 2022, 8:31 am
Icer's report suggests benefits of eli lilly's tirzepatide not better than other diabetes drugs
Institute for Clinical and Economic Review (ICER) casts doubts on Eli Lilly And Co's (NYSE: LLY) tirzepatide, a type II diabetes ...
February 16, 2022, 1:57 pm
Icer's report suggests benefits of eli lilly's tirzepatide not better than other diabetes drugs
Institute for Clinical and Economic Review (ICER) casts doubts on Eli Lilly And Co's (NYSE: LLY) tirzepatide, a type II diabetes ...
February 16, 2022, 1:57 pm
Icer's report suggests benefits of eli lilly's tirzepatide not better than other diabetes drugs
Institute for Clinical and Economic Review (ICER) casts doubts on Eli Lilly And Co's (NYSE: LLY) tirzepatide, a type II diabetes ...
February 16, 2022, 1:57 pm
Keep an eye on digital turbine's acquisitions to work and bring results
The APPS stock is a prime candidate for investors liking growth, however, the valuation is rich in a ye...
February 16, 2022, 1:10 pm
Keep an eye on digital turbine's acquisitions to work and bring results
The APPS stock is a prime candidate for investors liking growth, however, the valuation is rich in a ye...
February 16, 2022, 1:10 pm
Keep an eye on digital turbine's acquisitions to work and bring results
The APPS stock is a prime candidate for investors liking growth, however, the valuation is rich in a ye...
February 16, 2022, 1:10 pm
Biovaxys says studies on bvx-0320, its haptenized sars-cov-2 s-spike protein vaccine, suggest superior cardiac safety
BioVaxys Technology Corp has revealed that studies on BVX-0320, its haptenized SARS-CoV-2 s-spike protein vaccine ...
February 16, 2022, 9:48 am
Biovaxys says studies on bvx-0320, its haptenized sars-cov-2 s-spike protein vaccine, suggest superior cardiac safety
BioVaxys Technology Corp has revealed that studies on BVX-0320, its haptenized SARS-CoV-2 s-spike protein vaccine ...
February 16, 2022, 9:48 am
Biovaxys says studies on bvx-0320, its haptenized sars-cov-2 s-spike protein vaccine, suggest superior cardiac safety
BioVaxys Technology Corp has revealed that studies on BVX-0320, its haptenized SARS-CoV-2 s-spike protein vaccine ...
February 16, 2022, 9:48 am
Phirbo's (pahc) dyadic deal to fortify animal vaccine wing
Per the exclusive agreement, Phirbo (PAHC) together with Dyadic will continue development work to find a vaccine ...
February 15, 2022, 12:20 pm
Phirbo's (pahc) dyadic deal to fortify animal vaccine wing
Per the exclusive agreement, Phirbo (PAHC) together with Dyadic will continue development work to find a vaccine ...
February 15, 2022, 12:20 pm
Phirbo's (pahc) dyadic deal to fortify animal vaccine wing
Per the exclusive agreement, Phirbo (PAHC) together with Dyadic will continue development work to find a vaccine ...
February 15, 2022, 12:20 pm
Okyo pharma receives us regulatory approval to take dry disease candidate directly into a phase ii trial
OKYO Pharma Ltd said the US regulator has given it the green light to take its dry eye disease treatment directly into a phase II clinical trial. The ...
February 15, 2022, 2:36 am
Okyo pharma receives us regulatory approval to take dry disease candidate directly into a phase ii trial
OKYO Pharma Ltd said the US regulator has given it the green light to take its dry eye disease treatment directly into a phase II clinical trial. The ...
February 15, 2022, 2:36 am
Okyo pharma receives us regulatory approval to take dry disease candidate directly into a phase ii trial
OKYO Pharma Ltd said the US regulator has given it the green light to take its dry eye disease treatment directly into a phase II clinical trial. The ...
February 15, 2022, 2:36 am
Why proqr therapeutics stock got slammed again monday
Analysts are notably more bearish on the company following unhappy news about its leading drug candidat...
February 14, 2022, 6:23 pm